Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 11/20 | 0.54 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.54 |
| ▸ | JAK3 | P52333 | 1/20 | 0.54 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 4/20 | 0.38 |
| ▸ | GSK3A | P49840 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5962428 | 0.84 | MAPK14 (0.36) | MAPK14CSNK1DJAK3CSNK1EGSK3B | |
| SCHEMBL7677062 | 0.83 | MAPK14 (0.36) | MAPK14CSNK1DJAK3GSK3BGSK3A | |
| SCHEMBL5962380 | 0.81 | MAPK14 (0.57) | MAPK14CSNK1DGSK3BGSK3A | |
| SCHEMBL5962371 | 0.80 | MAPK14 (0.51) | MAPK14CSNK1DCSNK1EGSK3B | |
| SCHEMBL4974887 | 0.71 | MAPK14 (0.81) | MAPK14CSNK1DJAK3GSK3BGSK3A | |
| SCHEMBL5768899 | 0.71 | MAPK14 (0.58) | MAPK14CSNK1DJAK3 | |
| SCHEMBL5767150 | 0.70 | MAPK14 (0.55) | MAPK14CSNK1DJAK3 | |
| SCHEMBL5772817 | 0.69 | MAPK14 (0.56) | MAPK14CSNK1DJAK3 | |
| SCHEMBL5769737 | 0.69 | MAPK14 (0.47) | MAPK14CSNK1DJAK3CCNA2CDK2 | |
| SCHEMBL5769731 | 0.69 | MAPK14 (0.56) | MAPK14CSNK1DJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7026336-B1 | 4-pyridinylimidazol-2-ylhydrocarbyl amine, (thio)urea, carbamic acid or sulfonamide derivatives, e.g., (2-(4-(4-Chloro-3-methoxy-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl)-2-methyl-propyl)-carbamic acid tert-butyl ester; Raf kinase inhibitors for the treatment of neurotraumatic diseases | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-04-11 | — | — | US | disclosed |
| EP-1232153-B1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2004-11-03 | — | — | EP | disclosed |
| EP-1232153-A2 | IMIDAZOLE DERIVATIVES AND THEIR USE AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2002-08-21 | — | — | EP | disclosed |
| WO-2001038324-A2 | IMIDAZOLE DERIVATIVES AND THEIR USE AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-05-31 | — | — | WO | disclosed |